Contract Development and Manufacturing Organization (CDMO) Market is Estimated to Hit USD 465.24 Billion by 2032; Growing Demand for Effective Therapeutics and Clinical Trials Fuels Market Development

The global Contract Development and Manufacturing Organization (CDMO) market size stood at USD 238.92 billion in 2024. The market is anticipated to expand from USD 255.01 billion in 2025 to USD 465.24 billion by 2032, registering a CAGR of 9.0% during the forecast period (2025 – 2032).

Fortune Business Insights Presents this information in its report titled “Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Industry Analysis, By Service (CMO [API Manufacturing, Finished Product Manufacturing {Solid Dosage Forms, Injectables, and Others}, and Packaging] and CRO [Early Phase Development Services {Chemistry, Manufacturing, and Controls (CMC), Preclinical Service, and Discovery}, Clinical {Phase 1, Phase 2, Phase 3, and Phase 4}, Laboratory Service, and Others]), and Regional Forecast, 2025-2032”.

Contract Development and Manufacturing Organization (CDMOs) is an organization that provides complete services to pharmaceutical and biotechnology companies. From initial research to commercial production, these organizations provide inclusive services, which includes drug development and manufacturing. The mounting requirement for therapeutics in-effect, inadequate accessibility of in-house manufacturing capabilities, and manufacturing processes in small & mid-sized companies are among the major factors that are responsible for fueling the Contract Development and Manufacturing Organization (CDMO) market growth.

The COVID-19 pandemic resulted in a positive growth, due to the progress of drug development in the fiscal year 2020 for the virus. However, many biopharmaceutical and pharmaceutical industry players boosted their research and production skills in the late 2020s, to successfully create and distribute vaccines, medications, and testing kits for the COVID-19 virus. After the pandemic, there was substantial positive growth in the Contract Development and Manufacturing Organization (CDMO) market. Due to postponement of early-phase development and clinical trial services and the growing awareness related to manufacturing biologics led to the growth of the market.

Syneos Health’s Agreement with P3 Research Ltd Network Led to Product Expansion

In November 2023, an agreement was signed between Syneos Health and P3 Research Ltd Network to aid the company in expanding its clinical trial abilities in New Zealand across varied therapeutic areas. This agreement resulted in a significant growth in the Contract Development and Manufacturing Organization (CDMO).

Increasing Production of Medicine and Outsourcing of Clinical Trials Drive Market Growth

Due to the outsourcing of clinical trials and manufacturing processes of the medicines, the Contract Development and Manufacturing Organization (CDMO) market is rising significantly since the past few years. These factors allow pharmaceutical companies to decrease the operational costs because of the expertise and resources of CDMOs, which helps the companies dodge hefty investments in infrastructure and personnel. Additionally, CDMOs have specialized knowledge and innovative technology which might not be accessible for biotech and pharma companies’ in-house facilities.

However, the CDMOs must guarantee that their facilities and processes meet the standards of GMP, which are set by the U.S. FDA (Food and Drug Administration) and EMA (European Medicines Agency). These regulations meet rigorous documentation, validation, and quality control processes. Any failure in regard to these factors can lead to shutdown of facilities, or fines.

Enhancing Product Offerings by the Major Industry Players Leads to Solidifying their Market Positions

The rise in global contract development and manufacturing organization (CDMO) market growth is led by major key industry players, including Boehringer Ingelheim International GmbH, IQVIA Inc., and ICON plc. owing to their strategic partnerships to augment their product offerings. For instance, in July 2024, Boehringer Ingelheim International GmbH recently partnered up with Sino Biopharmaceutical Co. Ltd. to expand their services in the Chinese market for a wider audience. Moreover, companies such as Unither, Parexel International Corporation, Thermo Fisher Scientific Inc., and Vetter focus on innovative developments, including service expansion, partnerships, and collaborations.

Key Players Profiled in the Report

• IQVIA (U.S.)


• ICON plc (Ireland)


• Syneos Health (U.S.)


• Vetter (Germany)


• Parexel International (MA) Corporation (U.S.)


• Recipharm AB (Sweden)


• Curia Global, Inc. (U.S.)


• Thermo Fisher Scientific Inc. (U.S.)


• Unither Pharmaceuticals (France)


• DPT Laboratories, LTD. (U.S.)


• NextPharma Technologies (U.S.)


• Lonza (Switzerland)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502

Key Industry Development:

• February 2025 – Marionomed Biotech AG declared the successful closing of the sale of Carragelose business to French CDMO Unither Pharmaceuticals. 

Further Report Findings:

• By service, the CMO segment holds the dominant position in the Contract Development and Manufacturing Organization (CDMO) market share in 2024. Owing to the strategic partnerships among CDMOs and pharmaceutical/biotechnological companies for the development of therapeutics, this factor is boosting the segment’s growth.


• The North America region held the dominant position in the global market share in 2024 with a whopping USD 92.22 billion. This growth is due to the well-established CDMOs in the region, along with strategic partnerships with several pharmaceutical companies.


• Europe market comes below the North American region, accountable for the second leading market share in 2024. The growth of the market is due to the industry players’ concentration in participating in the medical conferences to raise awareness about their Contract Development and Manufacturing Organization (CDMO).

Table of Segmentation